Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
NCT ID: NCT01198808
Last Updated: 2012-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder
NCT03529890
Antitumor T Cell Responses in Patients With Bladder Cancer
NCT06334406
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
NCT05445648
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
NCT04726735
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
NCT04922047
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Hemoglobin \> 10g/dl
* Signed Informed Consent
* Karnofsky index \< 70%
Exclusion Criteria
* Severe comorbidities (e.g. NYHA III, end-stage renal disease)
* Chronic infectious disease (HIV, Tuberculosis)
* Immunosupression
* Severe psychiatric diseases
* Blood donation in the last 4 weeks
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technical University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Horn, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Urology, Technische Universität München
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urologische Klinik der Technischen Universität München
Munich, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IBT-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.